National Cancer Institute
Signal active
Investment Firm
Overview
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services.
Highlights
Founded
1937
Industry
Education
Employees
1001-5000
Investment
119
Lead Investment
101
Exits
13
Stages
N/A
Investor Type
Government Office
Location
Bethesda, Maryland, United States, North America
Contact Information
Social
Profile Resume
National Cancer Institute, established in 1937 and headquartered in United States, North America., specializes in investments across Biotechnology, Life Science, Health Care, Medical, Medical Device, Health Diagnostics, Product Research, Mental Health, Pharmaceutical, Therapeutics. The organization boasts a portfolio of 116 investments, with an average round size of $4.0M and 13 successful exits. Their recent investments include Xylyx Bio, Matter Bio, National Institutes of Health, National Institute of Environmental Health Sciences, Lamassu Pharma. The highest investment round they participated in was $6.7B. Among their most notable exits are Xylyx Bio and Matter Bio. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
National Cancer Institute has made 119 investments. Their most recent investment was on Jun 14, 2024, when Xylyx Bio raised $2.3M.
National Cancer Institute has made 27 diversity investments. Their most recent diversity investment was on Jul 12, 2023, when Amplified Sciences raised $400.0K.
investments
119
Diversity investments
27
Lead investments
101
Number of exits
13
Investments
119
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Jun 14, 2024 | Xylyx Bio | Biotechnology | 2.3M |
| Jul 11, 2024 | - | - | 2.1M |
| Jul 23, 2024 | - | - | 4.5M |
| Aug 08, 2024 | - | - | 2.0M |
Exits
13
Funding Timeline
Funding rounds
119
Investors
0
Funds
0
Funding Rounds
119
National Cancer Institute has raised 119 rounds. Their latest funding was raised on Aug 08, 2024 from a Grant - NERx Biosciences round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Jun 14, 2024 | Grant - Xylyx Bio | - | 2.3M | - |
| Jul 11, 2024 | Grant - Resolute Science | - | 2.1M | - |
| Jul 23, 2024 | Grant - Leuko | - | 4.5M | - |
| Aug 08, 2024 | Grant - NERx Biosciences | - | 2.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
News
Aug 28, 2024
MarketScreener - Fusion Antibodies expands agreement with National Cancer Institute
Funding Round
Aug 08, 2024
NERx Biosciences raised $2000000 on 2024-08-08 in Grant
Funding Round
Jul 23, 2024
Leuko raised $4500000 on 2024-07-23 in Grant
Funding Round
Jul 11, 2024
Resolute Science raised $2100000 on 2024-07-11 in Grant
Funding Round
Jun 14, 2024
Xylyx Bio raised $2260000 on 2024-06-14 in Grant
Funding Round
May 29, 2024
Matter Bio raised an undisclosed amount on 2024-05-29 in Grant